Impavido FDA Approval History
FDA Approved: Yes (First approved March 19, 2014)
Brand name: Impavido
Generic name: miltefosine
Dosage form: Capsules
Company: Paladin Labs Inc.
Treatment for: Leishmaniasis
Impavido (miltefosine) is an oral alkylphosphocholine antiparasitic for the treatment of leishmaniasis.
Development timeline for Impavido
|Mar 19, 2014||Approval FDA Approves Impavido to Treat Tropical Disease Leishmaniasis|
|Nov 13, 2013||Paladin Announces Extension of the Impavido PDUFA Date by Three Months|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.